The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients

Background. Identification of predictive molecular markers of triple-negative breast cancer (TNBC) will enable the evaluation of the efficacy of neoadjuvant chemotherapy (NACT) and define optimum approaches for the prognosis of the disease course in TNBC patients.The aim of the study was to examine...

Full description

Bibliographic Details
Main Authors:	N. N. Babyshkina, T. A. Dronova, E. A. Zambalova, M. V. Zavyalova, E. M. Slonimskaya, N. V. Cherdyntseva
Format:	Article
Language:	English
Published:	Siberian State Medical University (Tomsk) 2020-04-01
Series:	Бюллетень сибирской медицины
Subjects:	тройной негативный рак молочной железы неоадъювантная химиотерапия рецептор эпидермального фактора роста egfr полиморфизм генов
Online Access:	https://bulletin.ssmu.ru/jour/article/view/2675

Similar Items

Predictive Significance of Vascular Endothelial Growth Factor receptor VEGF-2 in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2016-11-01)

The status of epidermal growth factor receptor and topoisomerase IIα genes in triple-negative breast cancer cells
by: D. A. Karseladze, et al.
Published: (2014-08-01)

ROLE OF TRANSFORMING GROWTH FACTOR RECEPTOR B I TYPE (TGF-BRI) IN THE PROGRESSION OF THE LUMINAL BREAST CANCER SUBTYPE
by: N. N. Babyshkina, et al.
Published: (2017-06-01)

RELATIONSHIP OF THE IMMUNOLOGICAL PARAMETRES WITH NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN BREAST CANCER PATIENTS
by: Y. V. Kukharev, et al.
Published: (2016-02-01)

Evaluation of the role of rs2227983 polymorphism of EGFR gene in the development of allergic asthma
by: A. B. Аveryanov, et al.
Published: (2022-01-01)

PIK3CA mutations in breast cancer with low HER2 / neu expression
by: I. A. Pavlenko, et al.
Published: (2022-12-01)

EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)
by: O. D. Bragina, et al.
Published: (2021-10-01)

BRCA1 mRNA expression levels as an predictor of response to neoadjuvant chemotherapy in breast cancer
by: M. M. Tsyganov, et al.
Published: (2018-05-01)

Changes in angiogenesis markers during neoadjuvant treatment for locally advanced breast cancer
by: E. A. Kim, et al.
Published: (2014-08-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

PREDICTIVE VALUE OF MOLECULAR PARAMETERS IN PATIENTS WITH BASAL-LIKE TRIPL-NEGATIVE BREAST CANCER
by: О. D. Bragina, et al.
Published: (2016-02-01)

Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer
by: Yu. S. Sidorenko, et al.
Published: (2014-08-01)

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
by: O. O. Gordeeva, et al.
Published: (2020-11-01)

PROBLEM AND PERSPECTIVE TO IMPROVE MOLECULAR TESTING TO CHOOSE APPROPRIATE TARGET THERAPY
by: P. A. Gervas, et al.
Published: (2016-02-01)

IMMEDIATE RESPONSE TO NEOADJUVANT CHEMOTHERAPY INCLUDING CAPECITABINE AND LONG-TERM TREATMENT OUTCOMES OF OPERABLE BREAST CANCER
by: E. M. Slonimskaya, et al.
Published: (2016-07-01)

The Difficulties of Differential Diagnosis of the Bronchial Obstruction Syndrome
by: I. V. Demko, et al.
Published: (2021-08-01)

Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer
by: T. A. Dronova, et al.
Published: (2018-11-01)

MICROARRAY ANALYSIS OF DNA COPY NUMBER ABERRATION IN BREAST TUMOR: CORRELATION WITH THE EFFICACY OF NEOADJUVANT CHEMOTHERAPY
by: N. V. Litviakov, et al.
Published: (2016-02-01)

In vitro screening of effectiveness and antiproliferative effects of potential DDIT4 inhibitors for breast cancer cell lines
by: E. M. Zhidkova, et al.
Published: (2022-06-01)

Aberrations of the number of copies (CNA) in the genome of luminal B breast tumor
by: M. K. Ibragimova, et al.
Published: (2020-10-01)

Correlation of the value of sonoelastography strain ratio with the degree of pathological regression in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy
by: E. A. Bus’ko, et al.
Published: (2017-02-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)

Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)

MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS
by: P. V. Kazantseva, et al.
Published: (2016-07-01)

Gradient phenomenon of multidrug resistance gene expression in breast cancer during neoadjuvant chemotherapy is related to disease progression
by: N. V. Litviakov
Published: (2016-02-01)

Magnetic resonance imaging in evaluation of efficiency of neoadjuvant chemotherapy of breast cancer
by: A. V. Komyahov, et al.
Published: (2015-12-01)

Molecular biological subtypes of breast cancer in BRCA1 mutation carriers
by: N. I. Pospekhova, et al.
Published: (2021-01-01)

Role of positron emission tomography in predicting early tumor response to neoadjuvant chemotherapy for breast cancer
by: N. G. Chanchikova, et al.
Published: (2021-01-01)

ASSOCIATION OF NKT- AND ACTIVATED CD25<sup>+</sup> PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
by: A. I. Chertkova, et al.
Published: (2020-12-01)

ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE
by: D. B. Erdyneeva, et al.
Published: (2020-09-01)

Time course of changes in 6-sulfatoxymelatonin excretion in patients with breast cancer after various neoadjuvant chemotherapy options
by: Yu. S. Sidorenko, et al.
Published: (2014-07-01)

Results of combination treatment for triple-negative breast cancer
by: M. A. Sekundova, et al.
Published: (2014-07-01)

Genetic prognostic factors for neoadjuvant chemoradiotherapy for colorectal cancer
by: V. A. Grigorenko, et al.
Published: (2021-07-01)

Intensified dose-dense neoadjuvant chemotherapy using paclitaxel-gemcitabine and docetaxel-doxorubicin combinations for locally advanced breast cancer
by: I. V. Frai, et al.
Published: (2014-07-01)

EXPRESSION OF CD44 AND CD24 MARKERS IN BIOPSY SAMPLES OF TRIPLE NEGATIVE BREAST CANCER PATIENTS BEFORE TREATMENT
by: S. G. Smirnova, et al.
Published: (2020-09-01)

SINGLE NUCLEOTIDE POLYMORPHISMS IN BREAST TUMOR AND EXPRESSION OF ABC-TRANSPORTERS AFTER NEOADJUVANT CHEMOTHERAPY
by: M. M. Tsyganov, et al.
Published: (2016-02-01)

Gene expression analysis of ABC transporter family in breast tumors: relationship with chemotherapy effect and disease prognosis
by: M. M. Tsyganov, et al.
Published: (2020-09-01)

TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
by: A. D. Zikiryakhodzhaev, et al.
Published: (2017-06-01)

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
by: E. V. Karabina, et al.
Published: (2018-11-01)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy
by: M. K. Ibragimova, et al.
Published: (2022-03-01)